Adenosine (ADO) is an extracellular signaling molecule generated locally under conditions that produce ischemia, hypoxia, or inflammation. It is involved in modulating a range of physiological functions throughout the brain and periphery through the membrane-bound G protein-coupled receptors, called adenosine receptors (ARs) A₁AR, A₂AAR, A₂BAR, and A₃AR. These are therefore important targets for neurological, cardiovascular, inflammatory, and autoimmune diseases and are the subject of drug development directed toward the cyclic adenosine monophosphate and other signaling pathways. Initially using public data for A₁AR agonists we generated and validated a Bayesian machine learning model (Receiver Operator Characteristic of 0.87) that we used to identify molecules for testing. Three selected molecules, crisaborole, febuxostat and paroxetine, showed initial activity in vitro using the HEK293 A₁AR Nomad cell line. However, radioligand binding, β-arrestin assay and calcium flux assay did not confirm this A₁AR activity. Nevertheless, several other AR activities were identified. Febuxostat and paroxetine both inhibited orthosteric radioligand binding in the µM range for A₂AAR and A₃AR. In HEK293 cells expressing the human A₂AAR, stimulation of cAMP was observed for crisaborole (EC₅₀ 2.8 µM) and paroxetine (EC₅₀ 14 µM), but not for febuxostat. Crisaborole also increased cAMP accumulation in A₂BAR-expressing HEK293 cells, but it was weaker than at the A₂AAR. At the human A₃AR, paroxetine did not show any agonist activity at 100 µM, although it displayed binding with a Kᵢ value of 14.5 µM, suggesting antagonist activity.

We have now identified novel modulators of A₂AAR, A₂BAR and A₃AR subtypes that are clinically used for other therapeutic indications, and which are structurally distinct from previously reported tool compounds or drugs.

**Keywords:** ADORA, crisaborole, febuxostat, paroxetine, machine learning, adenosine receptor
INTRODUCTION

Adenosine (ADO) is an extracellular signaling molecule generated locally under conditions that produce ischemia, hypoxia, or inflammation and is involved in modulating a range of physiological functions throughout the brain and periphery by activating membrane-bound G protein-coupled receptors (GPCRs) (Borea et al., 2018). There are four subtypes of adenosine receptors (A1AR, A2AR, A2BR, and A3AR), which are the subject of vigorous drug development directed toward the cyclic adenosine monophosphate (cAMP) and other signaling pathways (Borea et al., 2016; Borea et al., 2018; Jacobson et al., 2019; Effendi et al., 2020). Adenosine receptors (ARs) were first classified according to their differential coupling to adenylate cyclase (AC) to regulate cAMP levels (Borea et al., 2018). Adenosine induces various biological effects associated with each adenosine receptor on the membrane surface of specific cells or tissues (Borea et al., 2018). Based upon sequence similarity and G protein-coupling specificity, A1AR and A2AR share ~49% sequence identity and preferentially couple to Gαi/o to inhibit AC (Effendi et al., 2020), which subsequently inhibits presynaptic glutamate release (Ciruela et al., 2006; Effendi et al., 2020). In contrast, A2AR and A2BR receptors, which are ~59% identical and couple to Gαs, are able to stimulate AC (Cheng et al., 2017) increasing levels of cAMP (Wardas, 2002). A1AR and A2AR receptors possess high affinity for ADO, while A2BR and A3AR receptors show relatively lower affinity. A1AR has been found to be widely distributed throughout the body. In the brain, it slows metabolic activity by a combination of actions. At neuronal synapses, it reduces synaptic vesicle release. A1AR is implicated in sleep promotion by inhibiting wake-promoting cholinergic neurons in the basal forebrain (Elmenhorst et al., 2007). A1AR is also present in smooth muscle throughout the vascular system (Fredholm et al., 2001; Tawil et al., 2005). A1AR has antiseizure activity and contributes to neuroprotection in models of neurodegeneration (Effendi et al., 2020). A1AR activation under hypoxic conditions leads to inhibition of presynaptic Ca²⁺ influx-related release of transmitters (Wu and Saggau, 1997) such as dopamine, acetylcholine, GABA, and, especially, glutamate, to generate neuroprotection (Stone et al., 2009).

A2AR has been linked to the anti-inflammatory effects of adenosine. Activation of A2AR reduces immune cell migration and produces tissue protection from ischemia/reperfusion injury (Okusa et al., 1999; Ohta and Sitkovsky, 2001). In contrast to other adenosine receptors, A2AR shows upregulated expression in many pathological conditions, such as inflammation, cancer, and hypoxia (Borea et al., 2016; Cekic and Linden, 2016; Gao and Jacobson, 2019). It interacts with Gs to induce the PKA signaling to increase cAMP and can trigger signaling transduction to elevate intracellular Ca²⁺ levels (Effendi et al., 2020). Activation of A2BR in mast cells might be useful in the treatment of asthma (Gao and Jacobson, 2017). A3AR is widespread with abundant expression in the lung and liver, and its activation reduces inflammation and chronic neuropathic pain (Jacobson et al., 2019). A3AR coupled to Gi proteins inhibits AC, decreases cAMP accumulation and PKA activity, while A3AR also increases Ca²⁺ levels and modulates PKC activity (Baraldi et al., 2012; Borea et al., 2018).

ARs are therefore important targets for neurological, cardiovascular, inflammatory, and autoimmune diseases (Borea et al., 2016; Borea et al., 2018). In addition, selective ligands are available for the different AR subtypes, which increase the chances to achieve spatially-specific modulation, representing a pharmacological opportunity to control addictive psychostimulant consumption, among many other health problems (Ballesteros-Yáñez et al., 2017). Initially, we used machine learning models to find agonists of A1AR and further expanded the testing against other subtypes, and we have identified novel AR modulators that are structurally distinct from previously reported tool compounds or drugs in clinical trials for targeting ADO receptors (Jacobson et al., 2019).

METHODS

Reagents

All test compounds were purchased from MedChemExpress (MCE, Monmouth Junction, NJ).

Machine Learning

Initially, an A1AR model was built with data reported in ChEMBL (Gaulton et al., 2017) (target 262). Assay Central® was used to build the model using EC₅₀ values, and non-druglike compounds such as Zn²⁺ (CHEMBL1201279), Li⁺ Cl⁻ (CHEMBL69710), and Li⁺ (CHEMBL1234004) were removed to increase the performance of the model. The ChEMBL compounds for ADORA1 consisted of 430 compounds with EC₅₀ values, and the corresponding Bayesian model was built using Assay Central®. Assay Central® has been used by our group in various drug discovery projects (Hernandez et al., 2018; Lane et al., 2018; Russo et al., 2018; Sandoval et al., 2018; Ekins et al., 2019a; Anantpadma et al., 2019; Ekins et al., 2019b; Dalecki et al., 2019; Wang et al., 2019; Ekins et al., 2020); its use as well as clarification on the applicability of the model statistics have been previously described. Metrics such as Receiver Operator Characteristic (ROC), Recall, Precision, F1 Score, Cohen’s Kappa and Matthew’s Correlation Coefficient are generated from internal five-fold cross-validation of the model. To maximize these internal performance statistics, the software can select a reasonable activity threshold, and generate predictions as well as applicability scores for any desired compound. Higher prediction scores are desirable as scores higher than 0.5 are assigned to active compounds (inhibitors). Higher applicability scores are also desirable as they ensure the representation of a given drug in the training set (Clark et al., 2015). The activity threshold for this external dataset was set to 100 nM, and Assay Central™ was used to generate the model performance metrics.

We have also used our updated Assay Central® software which now uses multiple classification algorithms described previously (Lane et al., 2018) as well as multiple regression algorithms.
including adaboost, Bayesian, elastic net, K-nearest neighbors (knn), random forest, support vector machine and XGBoost. We have further curated data available from ChEMBL for not only A1AR (ChEMBL226) but also A2AAR (ChEMBL251), A2BAR (ChEMBL255) and A3AR (ChEMBL256L). The data on CHEMBL comprise a diverse set of molecules and may comprise both full agonists and positive allosteric modulators (PAMs). For classification models the cut-off was set to 100 nM. 5-fold cross validation was performed for all algorithms except deep learning, which used the removal of 20% of the training set, in a stratified manner, and these were used as external test sets for models trained on the remainder of the data.

A1AR-cAMP Assay
This assay was performed using the screening services of Innoprot (Bizkaia, Spain). For screening of the initial compounds predicted by machine learning models to activate A1AR receptor, we used the HEK293 A1AR Nomad cell line, which consists of HEK293 cells stably expressing human A1AR with no tag. This cell line has been designed to assay compounds or analyze their capability to modulate the A1AR. When the agonist binds to A1AR in this engineered cell line a Gs, protein is activated, which in turn, triggers a cellular response mediated by cAMP inhibition. This cellular response can be measured by quantifying the increase in fluorescence intensity and its cellular distribution. An agonist assay was performed for 29 compounds (predicted to be active by the machine learning model) in the human recombinant HEK293 A1AR Nomad cell line using a fluorescence-based assay. An agonist effect of the compounds was measured by quantifying the changes in the fluorescence emission cAMP Nomad biosensor, this elevation of fluorescence was analyzed using a plate reader Synergy 2 (Biotek, Winooski, VT). The error bars represent the standard deviation among the three replicate wells. The 29 compounds were tested at 10 µM using nonselective AR agonist adenosine-5′-N-ethyluronamide (NECA) at 10 µM as a reference.

Radioligand Binding Assays
HEK293 cells stably expressing the human A1AR, A2AAR, A3AR were cultured in DMEM supplemented with 10% fetal bovine serum, 100 Units/ml penicillin, 100 µg/ml streptomycin, and 2 µmol/ml glutamine. To prepare cell suspension, cells were detached from culture plates by scraping into cold PBS and centrifuged at 250 g for 5 min. The pellets were resuspended in ice-cold PBS buffer (pH 7.4) and then homogenized. After homogenization and suspension, cells were centrifuged at 1,000 g for 10 min, and the pellet was discarded. The suspension was then re-centrifuged at 20,000 g for 60 min at 4°C. The pellets were resuspended in buffer containing 3 Units/ml adenosine deaminase (Worthington Biochemical, Lakewood, NJ) and incubated at 37°C for 30 min. The aliquots of membrane preparations were stored at −80°C until the binding experiments. For displacement binding assays, membrane preparations (20 µg proteins/tube) were incubated at 25°C for 60 min with a final concentration of [3H]DPCPX (0.5 nM), [3H]ZM241385 (1.0 nM), [3H]DPCPX (5.0 nM) and [125I]I-AB-MECA (0.1 nM) for A1AR, A2AAR, A3AR, respectively, in a mixture containing 50 µl of increasing concentrations of a test ligand in a total assay volume of 200 µl of 50 mM Tris HCl, pH 7.4, containing 10 mM MgCl2. Nonspecific binding was determined using 100 µM of XAC. The reaction was terminated by filtration with GF/B filters using a Brandel (Gaithersburg, MD) 24-channel harvester. Filters were placed in scintillation vials containing 5 ml of Hydrofluor scintillation buffer (National Diagnostics, Atlanta, GA) and counted using a Tricarb 2810TR liquid scintillation counter (PerkinElmer, Waltham, MA).

cAMP Assay in AR-Expressing HEK293 Cells
HEK293 cells were grown in 96-well plates in DMEM supplemented with 10% fetal bovine serum, 100 Units/ml penicillin, 100 µg/ml streptomycin, and 2 µmol/ml glutamine. After overnight growth, cells were treated with assay buffer containing phosphodiesterase (PDE) inhibitor rolipram (10 µM), and adenosine deaminase (3 units/ml) for 30 min (for A1AR, A2AAR and A3AR assays PSB603 (8-[4-[4-(4-chlorophenyl)piperazide-1-sulfonyl]phenyl]-1-propyloxanthine, 1 µM, was included to block the endogenous A3AR) followed by addition of agonists and a 20 min incubation. For A1AR and A2AR, after incubation with agonists for 20 min, forskolin (10 µM) was added and the mixture incubated for an additional 15 min. The reaction was terminated upon removal of the supernatant and addition of 100 µl Tween-20 (0.3%). Intracellular cAMP levels were measured with an ALPHAScreen cAMP assay kit as instructed by the manufacturer (PerkinElmer).

A1AR-bla U2OS-β-Arrestin Screen
This assay was performed using the screening services of Thermo Fisher (Waltham, MA). A1AR-bla U2OS cells are thawed and resuspended in Assay Media (Freestyle media) to a concentration of 312,500 cells/ml. 32 µl of cell suspension (10,000 cells) was added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media were incubated for 16–24 h in the plate at 37°C/5% CO2 in a humidified incubator. 4 µl aliquots of a 10X serial dilution of NECA (control agonist starting concentration, 500 nM) or compounds were added to appropriate wells of the plate. 4 µl of Assay Media was added to all wells to bring the final assay volume to 40 µl. The plate was incubated for 5 h at 37°C/5% CO2 in a humidified incubator. 8 µl of 1 µM substrate + Solution D Loading Solution was added to each well and the plate was incubated for 2 h at room temperature. The plate was read on a fluorescence plate reader.

PathHunter® β-Arrestin Assays
This assay was performed using the screening services of Eurofins (Luxembourg). The PathHunter® β-Arrestin assay monitors the activation of a A1AR in a homogenous, non-imaging assay format using a technology developed by DiscoverX called Enzyme Fragment Complementation (EFC) with β-galactosidase (β-Gal) as the functional reporter. The enzyme is split into two inactive complementary portions (EA for Enzyme Acceptor and PK for ProLink) expressed as fusion proteins in the cell. EA is
fused to β-Arrestin and PK is fused to the A3AR. When the A3AR is activated and β-Arrestin is recruited to the receptor, ED and EA complementation occurs, restoring β-Gal activity which is measured using chemiluminescent PathHunter Detection Reagents. PathHunter cell lines were expanded from freezer stocks according to standard procedures. Cells were seeded in a total volume of 20 μl into white walled, 384-well microplates and incubated at 37°C for the appropriate time prior to testing. For agonist determination, cells were incubated with sample to induce response. Intermediate dilution of sample stocks was performed to generate 5X sample in assay buffer. 5 μl of 5X sample was added to cells and incubated at 37°C or room temperature for 90–180 min. Vehicle concentration was 1%. Assay signal was generated through a single addition of 12.5 or 15 μl (50% v/v) of PathHunter Detection reagent cocktail, followed by a 1 h incubation at room temperature. Microplates were read following signal generation with a PerkinElmer Envision™ instrument for chemiluminescent signal detection. Compound activity was analyzed using CRIS data analysis suite (ChemInnovation, San Diego, CA). For agonist mode assays, percentage activity was calculated using the following formula: % Activity = 100% x (mean RLU of test sample–mean RLU of vehicle control)/(mean MAX control ligand–mean RLU of vehicle control).

**A1AR–Calcium Influx Assay**

This assay was performed using the screening services of Eurofins. Evaluation of the agonist activity of compounds at the human A1 receptor expressed in BA/F3 cells was determined by measuring their effect on cytosolic Ca2+ ion mobilization using a fluorimetric detection method. The cells were suspended in HBSS buffer (Invitrogen) complemented with 20 mM Hepes and then distributed in microplates at a density of 5 × 10⁴ cells/well. The fluorescent probe (Fluo8, AAT Bioquest, San Francisco, CA) mixed with probenecid in HBSS buffer (Invitrogen) complemented with 20 mM Hepes (Millipore, Burlington, MA) (pH 7.4) was then added into each well and equilibrated with the cells for 60 min at 30°C. Thereafter, the assay plates were positioned in a microplate reader (FlipR Tetra, Molecular Devices, San Jose, CA), which was used for the addition of the test compound, reference agonist or HBSS buffer (basal control), and for the measurements of changes in fluorescence intensity that varies proportionally to the free cytosolic Ca2+ ion concentration. For stimulated control measurements, N⁶-cyclopentyladenosine (CPA) at 0.25 μM was added in separate assay wells. The results were expressed as a percent of the control response to CPA at 0.25 μM. The standard reference agonist was CPA, which was tested in each experiment at several concentrations to generate a concentration-response curve from which its EC₅₀ value was calculated.

**RESULTS**

**Machine Learning**

Assay Central® (Clark and Ekins, 2015; Clark et al., 2015) is our in-house software that was used to curate the published A1AR data, build and validate machine learning models then enable predictions for molecules. This software has been previously used to build Bayesian machine learning models that generate predictions in toxicological and drug discovery projects (Lane et al., 2018; Russo et al., 2018; Zorn et al., 2019). The interpretation of the model metrics as well as the prediction and applicability scores have been described in detailed in previously published work (Clark et al., 2015; Lane et al., 2018; Russo et al., 2018; Zorn et al., 2019). While our Assay Central® software can select a reasonable threshold, 100 nM was set for the original A1AR Bayesian model (and subsequent models derived with additional algorithms). Compounds with an EC₅₀ lower than this threshold were considered active, and those above were considered inactive. The initial Bayesian model for A1AR agonists using literature data (Figure 1A), demonstrated a five-fold cross-validation ROC of 0.87, which is excellent. This model was then used to predict the SuperDrug library (Siramshetty et al., 2018) and our in-house library of compounds (predominantly consisting of FDA approved drugs and other compounds of interest), and 30 compounds were initially selected for testing for agonist activity in the A1AR cAMP assay (Supplementary Table S1).

Subsequently we have also built classification and regression models using our latest version of the Assay Central software for A1AR, A2AAR, A2BAR and A3AR (Supplementary Figures S1–S4). The classification machine learning models (100 nM cutoff) all had good 5-fold cross-validation statistics, and we have additionally generated regression models that can be used for scoring and selecting new compounds for testing in future. We used these additional models to predict activity of the hits selected from our initial models (Supplementary Table S2).

**A1AR Assays**

The initially selected 29 molecules were tested using the HEK293 A1AR Nomad cell line stably expressing human protein with no tag (Figure 1B). Activation of A1AR by an agonist engages G₁₁/₂/₃ or G₅ protein to inhibit adenylate cyclase and, therefore, decreases the cAMP concentration. Compounds were tested at 10 μM using NECA at 10 μM as the reference agonist. The fluorescence intensity was normalized to NECA at 10 μM and vehicle (DMSO) alone, which were considered 100% and 0%, respectively. The normalized results showed that febuxostat, BAY11-7082 ((E)-3-(4-methylphenylsulfonyl)-2-propenenitrile) and crisaborole showed a normalized activity with respect to the positive control of 94.53%, 98.74% and 98.52%, respectively (Figure 1B). Additionally, tilorone hydrochloride and paroxetine hydrochloride showed a normalized activity with respect to the positive control of 53.59% and 68.0%, respectively (Figure 1B). Other compounds predicted computationally by Assay Central showed an activity of less than 50% at the concentration tested. We therefore conducted additional assays with crisaborole, febuxostat and paroxetine using radioligand binding assays and measured dose response curves in the HEK293 A1AR assay using ALPHAScreen (Perkin Elmer) assay, as described below.

**Radioligand Binding**

The first step toward activation involves receptor binding. Thus, we have measured the inhibition of the binding of standard AR radioligands at the orthosteric site of three AR subtypes (Table 1).
No significant binding inhibition was observed at 100 µM for the three compounds at the human A1AR or human A2B AR or by crisaborole at human A2AAR and A3ARs. However, febuxostat and paroxetine both inhibited orthosteric radioligand binding in the µM range for A2AAR and A3AR.

Functional Activity on cAMP Levels in Transfected HEK Cells

Functional activity on cAMP levels in transfected HEK cells was determined for the three hit compounds. No A1AR agonist activity was observed (Figure 2). In HEK cells expressing the human A2AAR, stimulation of cAMP was observed for crisaborole (EC50 2.8 µM) and paroxetine (EC50 14 µM), but not for febuxostat. We did not measure A2B AR and A3AR effects of febuxostat in the cAMP cell assays. However, crisaborole is not an orthosteric A2AAR agonist, because it did not inhibit binding. Istradefylline, an A2A AR antagonist, only minimally affected crisaborole’s effect, suggesting a mechanism of crisaborole-induced cAMP accumulation that is different from standard full agonist NECA. Istradefylline (1 µM) had minimum effect, but it slightly lowered both basal value and the maximum effect. This concentration of istradefylline (Ki = 2.2 nM) should be sufficient to saturate the orthosteric A2AAR-binding site. Curiously, crisaborole also increased cAMP accumulation in A2B AR-expressing HEK293.
cells, but it was weaker than at the A2A AR. At the human A3AR, paroxetine did not show any agonist activity at 100 µM, although it displayed a binding Ki value of 14.5 µM, suggesting antagonist activity. A summary table of in vitro data for compounds tested against adenosine receptors is showed in Table 2.

A1AR–β-Arrestin Assay
We used A1AR-bla U2OS cells to test activation of A1AR receptor by crisaborole and paroxetine. This parental cell line stably expresses a beta-arrestin/TEV protease fusion protein and the beta-lactamase reporter gene under the control of a UAS response element. Paroxetine and crisaborole showed no activation in this system (Supplementary Figure S5). We also used a secondary assay PathHunter ® β-arrestin assay, which monitors the activation of A1AR in a homogenous, non-imaging assay format using a technology developed by DiscoverX called Enzyme Fragment Complementation (EFC) with β-galactosidase (β-Gal) as the functional reporter. This data was normalized to the maximal and minimal response observed in the presence of control agonist CPA and vehicle (Supplementary Figure S6), and no activation of the A1AR receptor was observed in this assay at the maximum crisaborole concentration of 20 µM.

A1AR–Calcium Influx Assay
Crisaborole was tested using cellular and nuclear receptor functional Assays (Eurofins) for calcium influx assay and showed no activity of the A1AR receptor at the maximum concentration tested (20 µM) (Supplementary Figure S7).

DISCUSSION
While there have been several previous attempts to use machine learning for ARs (Saad et al., 2019; Wang et al., 2021), few have performed external validation. One recent study used deep learning combined with pharmacophore and docking approaches to identify novel A1/A2A antagonists (Wang et al., 2021). In contrast, we were keen to use machine learning alone to potentially repurpose existing drugs for ARs. Using our initial machine learning model, we have identified crisaborole as weakly binding to A1AR, but without activity on the cAMP, β-arrestin and calcium influx assays. However, crisaborole can activate A2AAR and A2BAR at the highest concentrations examined. Unexpectedly, the presence of an orthosteric A2AAR antagonist istradefylline did not antagonize the effect of crisaborole, suggesting a mechanism of crisaborole-induced cAMP accumulation that is different from standard full agonist NECA. Paroxetine induced weak activation of A2A AR, but...
no activation of A3AR, despite a binding Kd of 14.5 ± 9.7 µM. The lack of A3AR activation suggested that paroxetine is an antagonist at this subtype. The structures of the three hit compounds do not resemble AR-targeting drugs that have been studied in clinical trials previously (Jacobson et al., 2019) (Supplementary Figure S8).

We evaluated the activity of crisaborole using several different in vitro assays. Crisaborole is an inhibitor of phosphodiesterase 4 (PDE4), which is responsible for the hydrolysis and subsequent inactivation of cyclic nucleotides such as cAMP. A1AR activation promotes inhibition of adenylyl cyclase and consequently inhibits cAMP production leading to the inhibition of presynaptic glutamate release (Wardas, 2002). Thus, since crisaborole is an inhibitor of PDE4 and A1AR, it may have different effects on cAMP levels that are antagonistic. When crisaborole was tested in a second independent β-arrestin assay using the A1AR-bla U2OS Cells and PathHunter technology, it showed no agonist activity at the A1AR (Supplementary Figures S5, S6) and had no activity in the calcium influx assay (Supplementary Figure S7).

In the United States, crisaborole is indicated for topical treatment of mild to moderate atopic dermatitis in people 3 months of age and older (Schlessinger et al., 2020). Crisaborole enhances cellular control of inflammation by inhibiting PDE4 and its ability to degrade intracellular cAMP. Apparent A2AR agonist-like activity of crisaborole in combination with its PDE4 inhibitory activity may contribute when used topically in the clinic, regardless of the mechanism of A2AR activation.

The medicinal chemistry surrounding the development of novel adenosine receptor ligands has largely been driven by derivatization of the adenosine and other purine-like scaffolds to gain understanding of the structure-activity relationships especially in the early stages to distinguish between A1AR and A2AR (Geldenhuys et al., 2017). From these studies, novel scaffolds were developed, such as the A2AR antagonist core 8-styrylxanthine. It was discovered that substitution of the styryl moiety with an 8-phenoxymethyl moiety leads to a dual A1/A2A receptor antagonist (Harmsse et al., 2016). The current study provides additional scaffolds based on approved drugs that could be modified in the future to improve activities against these receptors.

The A2AAR receptor is also expressed in the brain, where it has important roles in the regulation of glutamate and dopamine release, making it a potential therapeutic target for the treatment of conditions such as insomnia, pain, depression, and Parkinson’s disease (Borea et al., 2018). A2AAR is recognized as the main adenosine subtype located in the striatum, where it is colocalized with dopamine D2 receptors (D2R). This results in A2AAR/D2R heteromers that have a crucial role in the modulation of motor function (Borea et al., 2018). A2AAR may be a therapeutic target in Alzheimer’s disease, Huntington’s disease, epilepsy, acute and chronic stress, and memory fear (Borea et al., 2018). Pharmacological agents that increase the activation of A1AR in response to adenosine would be useful for the treatment of CNS, cardiovascular, and inflammatory pathologies (Borea et al., 2018). Coactivation of two AR subtypes might be therapeutically beneficial, such as both A1AR and A3AR in cardioprotection (Jacobson et al., 2005). Understanding the mechanisms of drug actions at GPCRs and translating this understanding into more selective and effective medicines remains a challenge (May et al., 2007). The effects of an allosteric modulator on ligand efficacy and on affinity at the orthosteric site do not always correlate, such that a modulator can increase the affinity of an orthosteric ligand while decreasing the efficacy and vice versa (May et al., 2007).

**CONCLUSION**

The goal of this work was to use machine learning approaches to assist in identifying new molecules to modulate ARs. In the process we have identified several approved drugs with in vitro functional activity against the A2AAR, A2BAR and A3AR subtypes, which could potentially be repurposed. The three molecules derived from machine learning each had a distinct pharmacological activity, which diverged in the different in vitro assays used and, in some cases, suggested non-canonical interaction with these receptors. Subsequent pharmacological characterization, including the use of AR-knockout mice (Xiao et al., 2019), will be needed to better understand their respective modes of action in future. The data generated in this study may also be used to improve our machine learning models and provide further structural diversity for starting points for medicinal chemistry efforts for AR modulators.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

**AUTHOR CONTRIBUTIONS**

AP performed data analysis, drafted the manuscript, assisted in providing funding for this project. SE drafted the manuscript and assisted in providing funding for this project. Z-GG and KJ performed pharmacological studies and data analysis. All authors contributed to conceptual design and editing of the manuscript.

**FUNDING**

We kindly acknowledge NIH funding: R44GM122196-02A1 from NIGMS, NIEHS for 1R43ES031038-01 and 3R43ES031038-01S1, NIDDK Intramural Res. for ZIADK031117. “Research reported in this publication was supported by the National Institute of Environmental Health Sciences of the National Institutes of Health under Award Number R43ES031038. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.”
ACKNOWLEDGMENTS

We kindly acknowledge assistance from Dr. Fabio Urbina and Ms. Kimberley Zorn. Dr. Alex M. Clark (Molecular Materials Informatics, Inc.) is thanked for support of the earlier version of Assay Central.”

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2022.920643/full#supplementary-material
Siramshetty, V. B., Eckert, O. A., Gohlke, B. O., Goede, A., Chen, Q., Devarakonda, P., et al. (2018). SuperDRUG2: A One Stop Resource for Approved/Marketed Drugs. Nucleic Acids Res. 46 (D1), D1137–D1143. doi:10.1093/nar/gka1088

Stone, T. W., Cerutti, S., and Abbracchio, M. P. (2009). Adenosine Receptors and Neurological Disease: Neuroprotection and Neurodegeneration. Handb. Exp. Pharmacol. 193, 535–559. doi:10.1007/978-3-540-89615-9_17

Tawfiq, H. E., Schnermann, J., Oldenburg, P. J., and Mustafa, S. J. (2005). Role of A1 Adenosine Receptors in Regulation of Vascular Tone. Am. J. Physiol. Heart Circ. Physiol. 288 (3), H1411–H1416. doi:10.1152/ajpheart.00684.2004

Wang, M., Hou, S., Wei, Y., Li, D., and Lin, J. (2021). Discovery of Novel Dual Adenosine A1/A2A Receptor Antagonists Using Deep Learning, Pharmacophore Modeling and Molecular Docking. PLoS Comput. Biol. 17 (3), e1008821. doi:10.1371/journal.pcbi.1008821

Wang, P. F., Neiner, A., Lane, T. R., Zorn, K. M., Ekins, S., and Kharasch, E. D. (2019). Halogen Substitution Influences Ketamine Metabolism by Cytochrome P450 2B6: In Vitro and Computational Approaches. Mol. Pharm. 16 (2), 898–906. doi:10.1021/acs.molpharmaceut.8b01214

Wardas, J. (2002). Neuroprotective Role of Adenosine in the CNS. Pol. J. Pharmacol. 54 (4), 313–326.

Wu, L. G., and Saggau, P. (1997). Presynaptic Inhibition of Elicited Neurotransmitter Release. Trends Neurosci. 20 (5), 204–212. doi:10.1016/s0166-2236(96)01015-6

Xiao, C., Liu, N., Jacobson, K. A., Gavrilova, O., and Reitman, M. L. (2019). Physiology and Effects of Nucleosides in Mice Lacking All Four Adenosine Receptors. PLoS Biol. 17 (3), e3000161. doi:10.1371/journal.pbio.3000161

Ye, Q., Li, M., Zhou, Y., Pang, T., Xu, L., Cao, J., et al. (2013). Synthesis and Biological Evaluation of 3-Benzisoxazolyl-4-Indolylmaleimides as Potent, Selective Inhibitors of Glycogen Synthase Kinase-3β. Molecules 18 (5), 5498–5516. doi:10.3390/molecules18055498

Zhang, H. C., White, K. B., Ye, H., McComsey, D. F., Derian, C. K., Addo, M. F., et al. (2003). Macrocyclic Bisindolylmaleimides as Inhibitors of Protein Kinase C and Glycogen Synthase Kinase-3. Bioorg. Med. Chem. Lett. 13 (18), 3049–3053. doi:10.1016/s0960-894x(03)00644-9

Zorn, K. M., Lane, T. R., Russo, D. P., Clark, A. M., Makarov, V., and Ekins, S. (2019). Multiple Machine Learning Comparisons of HIV Cell-Based and Reverse Transcriptase Data Sets. Mol. Pharm. 16 (4), 1620–1632. doi:10.1021/acs.molpharmaceut.8b01297

Conflict of Interest: SE is the owner and AP is an employee of Collaborations Pharmaceuticals, Inc.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Puhl, Gao, Jacobson and Ekins. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.